Apogee Therapeutics enters manufacturing agreement with Samsung Biologics for APG777 drug substance

Apogee Therapeutics, Inc.

Master Services Agreement with Samsung Biologics for manufacture and supply of APG777 drug substance for clinical development and commercial sale if approved.
Initial Project Specific Agreement for clinical batches, process characterization/validation, and process performance qualification lots at Samsung's Incheon facility.
Minimum purchase quantities under Initial PSA; commercial supply PSA from 2029-2034 with minimum commitments; exit fee high single digit millions if not entered.
MSA terminates February 2035; Initial PSA terminates December 2034; termination rights for material breach, insolvency, force majeure.
Upon termination, Samsung to assist with technology transfer; without-cause termination results in payment for remaining product commitment.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.